Rallybio (RLYB) Net Equity Issued and Repurchased (2022 - 2026)

Rallybio (RLYB) posted Net Equity Issued and Repurchased of $3000.0 for Q1 2026, down 85.71% sequentially from $21000.0 in Q3 2022.

Rallybio (RLYB) Net Equity Issued and Repurchased (2022 - 2026) Analysis & Trends

Rallybio has reported Net Equity Issued and Repurchased for 2 years, with the latest figure at $3000.0 in Q1 2026.

Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $3000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3000.0 (changed N/A YoY) and the FY2024 annual result came in at $5.4 million, changed N/A from the prior year.
Net Equity Issued and Repurchased eased to $3000.0 in Q1 2026 per RLYB's latest filing, from $21000.0 in the prior quarter.
Over five years, Net Equity Issued and Repurchased peaked at $21000.0 in Q3 2022 and troughed at $3000.0 in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Equity Issued and Repurchased (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	49.20 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	Rallybio	94.61 Mn	94.61 Mn	-	-

Download Data